Show simple item record

dc.contributor.authorLogue, John P
dc.contributor.authorMagee, Brian
dc.contributor.authorHunter, Robin D
dc.contributor.authorMurdoch, R D
dc.date.accessioned2010-07-02T16:02:07Z
dc.date.available2010-07-02T16:02:07Z
dc.date.issued1991-09
dc.identifier.citationThe antiemetic effect of granisetron in lower hemibody radiotherapy. 1991, 3 (5):247-9 Clin Oncolen
dc.identifier.issn0936-6555
dc.identifier.pmid1657114
dc.identifier.doi10.1016/S0936-6555(05)80871-4
dc.identifier.urihttp://hdl.handle.net/10541/107113
dc.description.abstractRadiotherapy-induced emesis is poorly controlled with existing antiemetics. 5-Hydroxytryptamine (5HT3) receptor antagonists are a new class of antiemetics which have been demonstrated to be effective in controlling cytotoxic-induced emesis. We have prospectively studied the antiemetic efficacy of the 5HT3 receptor antagonist granisetron in an open non-randomized efficacy and toxicity study, at two dose levels, in patients receiving lower hemibody radiotherapy for multiple bone metastases. Of the 22 patients studied, 13 patients received 20 micrograms/kg and nine patients 40 micrograms/kg of granisetron, administered as an intravenous infusion 1 h before radiotherapy. Radiotherapy was administered as a single exposure to the lower half body to a midline dose of 8 Gy. A complete response (no nausea or vomiting) was observed in 9/13 patients at the lower dose level and 6/9 patients at the higher level. No major adverse events were recorded. We conclude that granisetron is a well-tolerated and effective antiemetic agent in radiotherapy-induced emesis. Formal comparison with conventional antiemetic agents in this situation is required.
dc.language.isoenen
dc.subjectBone Canceren
dc.subject.meshAged
dc.subject.meshAntiemetics
dc.subject.meshBone Neoplasms
dc.subject.meshFemale
dc.subject.meshGranisetron
dc.subject.meshHumans
dc.subject.meshIndazoles
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshProspective Studies
dc.subject.meshRadiotherapy
dc.subject.meshVomiting
dc.titleThe antiemetic effect of granisetron in lower hemibody radiotherapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy and Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalClinical Oncologyen
html.description.abstractRadiotherapy-induced emesis is poorly controlled with existing antiemetics. 5-Hydroxytryptamine (5HT3) receptor antagonists are a new class of antiemetics which have been demonstrated to be effective in controlling cytotoxic-induced emesis. We have prospectively studied the antiemetic efficacy of the 5HT3 receptor antagonist granisetron in an open non-randomized efficacy and toxicity study, at two dose levels, in patients receiving lower hemibody radiotherapy for multiple bone metastases. Of the 22 patients studied, 13 patients received 20 micrograms/kg and nine patients 40 micrograms/kg of granisetron, administered as an intravenous infusion 1 h before radiotherapy. Radiotherapy was administered as a single exposure to the lower half body to a midline dose of 8 Gy. A complete response (no nausea or vomiting) was observed in 9/13 patients at the lower dose level and 6/9 patients at the higher level. No major adverse events were recorded. We conclude that granisetron is a well-tolerated and effective antiemetic agent in radiotherapy-induced emesis. Formal comparison with conventional antiemetic agents in this situation is required.


Files in this item

This item appears in the following Collection(s)

Show simple item record